We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Show more
A healthcare company based out of North Carolina is turning heads so far during Tuesday’s session after the company announced that it plans to submit its Dordaviprone for To read the full...
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on...
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerixβs Board of Directors granted inducement...
DURHAM, N.C., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...
β Phase 3 ACTION Study On-Track with First Interim Overall Survival Data Expected Third Quarter 2025 β β IDMC Recommends Continuing Conduct of ACTION Study As-Is Following Preplanned Safety Review...
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ChimerixΒ (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.42 | 14.3835616438 | 2.92 | 3.34 | 2.705 | 1869741 | 2.88189211 | CS |
4 | 2.4481 | 274.481444108 | 0.8919 | 3.39 | 0.8101 | 12203227 | 2.61341007 | CS |
12 | 2.4 | 255.319148936 | 0.94 | 3.39 | 0.8 | 4000528 | 2.55610785 | CS |
26 | 2.4514 | 275.872158451 | 0.8886 | 3.39 | 0.75 | 2118411 | 2.3731219 | CS |
52 | 2.4022 | 256.152697803 | 0.9378 | 3.39 | 0.75 | 1249584 | 2.18893579 | CS |
156 | -3.79 | -53.1556802244 | 7.13 | 7.15 | 0.75 | 1538168 | 2.26827847 | CS |
260 | 1.21 | 56.8075117371 | 2.13 | 11.5696 | 0.75 | 1218414 | 3.10791838 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions